MEDICAL UPDATE: 3TC Trials

MEDICAL UPDATE: 3TC Trials

Being Alive Newsletter; Beling Alive/Los Angeles - September 93
Mark Katz MD and reported by Jim Stoecker

As mentioned in last month's update, COMBAT (213.469.5888) is sponsoring a local Phase III trial of the reverse transcriptase inhibitor 3TC. Trial NUCA 3001 will test 3TC vs. AZT vs. the two in combination among subjects in the 200-500 CD4 range with no prior AZT use. NUCA 3002 will test AZT/3TC combinations in different doses against combination AZT/ddC in subjects who are in the 100-300 CD4 range and have had at least 24 weeks prior use of AZT.

The trial will include the measurement of more parameters than usual, including viral load, development of resistance, and SI (syncytia inducing) strains. In vitro data indicate that 3TC may be effective in reversing resistance to AZT.
930900
BA930904

AEGiS is made possible through unrestricted grants from Roxane Laboratories, the National Library of Medicine, and donations from users like you. Always watch for outdated information. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1993 - Beings Alive. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. Being Alive, 621 N. San Vicente Blvd., West Hollywood, CA 90069, Tel - 310.289.2551; FAX - 310.289.9866; Email: BeiAlive@aol.com http://www.beingalivela.org/

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1993. AEGIS.